Esketamine for reducing perioperative opioid use in laparoscopic colorectal cancer surgery: impact on postoperative nausea and vomiting at 48 hours
Not Applicable
Completed
- Conditions
- Postoperative nausea and vomitingDigestive System
- Registration Number
- ISRCTN25778550
- Lead Sponsor
- Changzhou Science and Technology Bureau
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 84
Inclusion Criteria
- Patients undergoing laparoscopic radical resection of colorectal cancer2. Aged 18-80 years old, no gender limitation3. ASA I-III4. Postoperative agreed to use the PCIA5. Voluntarily signed informed consent
Exclusion Criteria
- People with severe consciousness disorder or mental system disease and cognitive dysfunction2. Merge heart liver and kidney and other viscera function disorder3. Arrhythmia (atrial fibrillation or atrioventricular conduction block between arrhythmia etc.) or after cardiac pacemaker implantation4. BP or 180/100 MMHG, untreated or poor control of blood pressure5. Increased intracranial pressure6. Glaucoma7. Without treatment, and treatment of hyperthyroidism8. Known for esketamine injection, the active ingredient or complementary makings allergies9. Alcohol or alcohol addiction10. Have a vision, hearing, or language barrier and cannot communicate and cooperate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The occurrence and intensity of postoperative nausea and vomiting (PONV) measured using the PONV Impact Scale at 1, 24, and 48 h after surgery
- Secondary Outcome Measures
Name Time Method